TY - JOUR
TI - The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study
AU - Bosco, P.
AU - Redolfi, A.
AU - Bocchetta, M.
AU - Ferrari, C.
AU - Mega, A.
AU - Galluzzi, S.
AU - Austin, M.
AU - Chincarini, A.
AU - Collins, D.L.
AU - Duchesne, S.
AU - Maréchal, B.
AU - Roche, A.
AU - Sensi, F.
AU - Wolz, R.
AU - Alegret, M.
AU - Assal, F.
AU - Balasa, M.
AU - Bastin, C.
AU - Bougea, A.
AU - Emek-Savaş, D.D.
AU - Engelborghs, S.
AU - Grimmer, T.
AU - Grosu, G.
AU - Kramberger, M.G.
AU - Lawlor, B.
AU - Mandic Stojmenovic, G.
AU - Marinescu, M.
AU - Mecocci, P.
AU - Molinuevo, J.L.
AU - Morais, R.
AU - Niemantsverdriet, E.
AU - Nobili, F.
AU - Ntovas, K.
AU - O'Dwyer, S.
AU - Paraskevas, G.P.
AU - Pelini, L.
AU - Picco, A.
AU - Salmon, E.
AU - Santana, I.
AU - Sotolongo-Grau, O.
AU - Spiru, L.
AU - Stefanova, E.
AU - Popovic, K.S.
AU - Tsolaki, M.
AU - Yener, G.G.
AU - Zekry, D.
AU - Frisoni, G.B.
JO - American Journal of Alzheimer's Disease and other Dementias
PY - 2017
VL - 13
TODO - 9
SP - 1013-1023
PB - ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN - 1533-3175
TODO - 10.1016/j.jalz.2017.01.019
TODO - amyloid beta protein[1-42];  fluorodeoxyglucose f 18;  tau protein;  amyloid beta protein;  amyloid beta-protein (1-42);  peptide fragment;  tau protein, aged;  Alzheimer disease;  Article;  automated hippocampal volumetry;  automation;  brain atrophy;  brain scintiscanning;  brain size;  cerebrospinal fluid;  clinical assessment;  clinical evaluation;  cognitive defect;  diagnostic value;  executive function test;  female;  hippocampus;  human;  image segmentation;  language test;  long term memory;  lumbar puncture;  major clinical study;  male;  medial temporal lobe;  memory test;  Mini Mental State Examination;  nerve biopsy;  neuropsychological test;  nuclear magnetic resonance imaging;  nuclear magnetic resonance scanner;  positron emission tomography;  priority journal;  single photon emission computed tomography;  visual-spatial ability test;  volumetry;  Alzheimer disease;  clinical trial;  cognitive defect;  complication;  computer assisted diagnosis;  diagnostic imaging;  differential diagnosis;  disease exacerbation;  Europe;  hippocampus;  metabolism;  multicenter study;  pathology, Alzheimer Disease;  Amyloid beta-Peptides;  Cognition Disorders;  Diagnosis, Computer-Assisted;  Diagnosis, Differential;  Disease Progression;  Europe;  Female;  Fluorodeoxyglucose F18;  Hippocampus;  Humans;  Male;  Neuropsychological Tests;  Peptide Fragments;  Positron-Emission Tomography;  tau Proteins;  Tomography, Emission-Computed, Single-Photon
TODO - Introduction Hippocampal volume is a core biomarker of Alzheimer's disease (AD). However, its contribution over the standard diagnostic workup is unclear. Methods Three hundred fifty-six patients, under clinical evaluation for cognitive impairment, with suspected AD and Mini–Mental State Examination ≥20, were recruited across 17 European memory clinics. After the traditional diagnostic workup, diagnostic confidence of AD pathology (DCAD) was estimated by the physicians in charge. The latter were provided with the results of automated hippocampal volumetry in standardized format and DCAD was reassessed. Results An increment of one interquartile range in hippocampal volume was associated with a mean change of DCAD of −8.0% (95% credible interval: [−11.5, −5.0]). Automated hippocampal volumetry showed a statistically significant impact on DCAD beyond the contributions of neuropsychology, 18F-fluorodeoxyglucose positron emission tomography/single-photon emission computed tomography, and cerebrospinal fluid markers (−8.5, CrI: [−11.5, −5.6]; −14.1, CrI: [−19.3, −8.8]; −10.6, CrI: [−14.6, −6.1], respectively). Discussion There is a measurable effect of hippocampal volume on DCAD even when used on top of the traditional diagnostic workup. © 2017 the Alzheimer's Association
ER -